Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
May 30, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
May 28, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 09, 2024 16:10 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
March 26, 2024 06:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 21, 2024 07:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
November 13, 2023 07:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
October 30, 2023 12:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE...
February 28, 2023 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the...
December 27, 2022 07:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5...